Home › Trial NCT01483144
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
- Trial IDNCT01483144
- StatusCompleted
- PhasePhase 3
- Study typeInterventional
- SponsorCancer Prevention Pharmaceuticals, Inc.
- Enrollment171
- Start date2013-10
- ConditionsFamilial Adenomatous Polyposis
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.